Precipio (NASDAQ:PRPO – Get Free Report) and American Well (NYSE:AMWL – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Precipio and American Well, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Precipio | 1 | 0 | 0 | 0 | 1.00 |
| American Well | 1 | 3 | 1 | 0 | 2.00 |
American Well has a consensus price target of $8.60, suggesting a potential downside of 20.45%. Given American Well’s stronger consensus rating and higher possible upside, analysts plainly believe American Well is more favorable than Precipio.
Insider and Institutional Ownership
Profitability
This table compares Precipio and American Well’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Precipio | -3.57% | -6.73% | -4.49% |
| American Well | -37.02% | -32.11% | -24.12% |
Earnings & Valuation
This table compares Precipio and American Well”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Precipio | $24.05 million | 1.76 | -$360,000.00 | ($0.47) | -50.38 |
| American Well | $249.32 million | 0.72 | -$95.70 million | ($5.42) | -1.99 |
Precipio has higher earnings, but lower revenue than American Well. Precipio is trading at a lower price-to-earnings ratio than American Well, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Precipio has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, American Well has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500.
About Precipio
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
About American Well
American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members. It provides Carepoint devices comprising carts, peripherals, tablets, and TVs, which serve as digital access points in clinical settings. In addition, the company offers Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, acute psychiatry, lactation counseling, and nutrition services. Further, it provides professional services to facilitate implementation, workflow design, systems integration, and service expansion for its products, as well as patient and provider engagement services. The company sells its products through field sales professionals, channel partners, and value-added resellers. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.
